Kezar Life Sciences, Inc. (KZR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kezar Life Sciences, Inc. (KZR) trades at $7.29 with AI Score 44/100 (Grade C). Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases and cancer. Market cap: $53.86M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for KZR: KZR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KZR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KZR: the 1 perspectives are evenly split.
How is this calculated? →Kezar Life Sciences, Inc. (KZR) Healthcare & Pipeline Overview
Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm specializing in small molecule therapeutics for immune-mediated diseases and cancer, with KZR-616 leading its pipeline in Phase 2 trials, positioning it within a competitive landscape of innovative drug developers.
What Is the Investment Thesis for KZR?
Kezar Life Sciences presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The primary value driver is KZR-616, currently in Phase 2 trials, with positive data readouts expected over the next 12-24 months potentially driving significant stock appreciation. Successful clinical trial outcomes and subsequent regulatory approvals would validate the company's immunoproteasome inhibition approach. However, the company's valuation is highly dependent on the success of KZR-616 and its other pipeline candidates. Failure to achieve positive clinical results or secure regulatory approvals would negatively impact the stock. With a market cap of $53.86M and a beta of 0.43, Kezar exhibits moderate volatility. Investors should carefully weigh the potential upside against the inherent risks of biotechnology investing.
Based on FMP financials and quantitative analysis
KZR Key Highlights
- KZR-616 is in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, targeting significant unmet medical needs.
- KZR-616 is also in Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis, expanding its potential application.
- KZR-261, a novel first-in-class protein secretion inhibitor, is in preclinical development, representing a potential future growth driver.
- The company has a market capitalization of $53.86M, reflecting its early-stage development profile.
- Kezar Life Sciences was founded in 2015, indicating a relatively young company with significant growth potential.
Who Are KZR's Competitors?
KZR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KZR's Key Strengths?
- Promising lead product candidate (KZR-616) in Phase 2 clinical trials.
- Novel approach to treating immune-mediated diseases and cancer.
- Experienced management team with expertise in drug development.
What Are KZR's Weaknesses?
- Reliance on the success of KZR-616 and other pipeline candidates.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk of clinical trial failure and regulatory setbacks.
What Could Drive KZR Stock Higher?
- Data readouts from Phase 2 clinical trials of KZR-616 in lupus nephritis, dermatomyositis, and polymyositis.
- Initiation of clinical trials for KZR-261.
- Potential for strategic partnerships and collaborations.
What Are the Key Risks for KZR?
- Financial-distress signal — its Altman Z-Score of 1.05 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-58.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for KZR-616 or other pipeline candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from other companies developing therapies for immune-mediated diseases and cancer.
- Dependence on securing additional funding to support research and development activities.
What Are the Growth Opportunities for KZR?
- Expansion of KZR-616 into new indications: The success of KZR-616 in its current Phase 2 trials could pave the way for its expansion into other immune-mediated diseases. The market for autoimmune disease treatments is substantial, with a global market size estimated at billions of dollars. Positive clinical data and regulatory approvals could significantly increase Kezar's market opportunity and revenue potential.
- Advancement of KZR-261 into clinical development: KZR-261, a novel first-in-class protein secretion inhibitor, represents a potential breakthrough in treating various diseases. Moving KZR-261 into clinical trials would mark a significant milestone for Kezar, potentially attracting partnerships and further investment. The market for protein secretion inhibitors is nascent but promising, with potential applications in oncology and immunology.
- Strategic partnerships and collaborations: Kezar could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing Kezar's ability to bring its therapies to market. The biotechnology industry is characterized by frequent collaborations, with companies leveraging each other's strengths to maximize their potential.
- Expansion of the pipeline through internal discovery and licensing: Kezar can expand its pipeline by identifying new drug targets and developing additional small molecule therapeutics. The company can also license promising compounds from other research institutions or biotechnology firms. A diversified pipeline reduces risk and increases the likelihood of bringing successful therapies to market. The biotechnology industry is constantly evolving, with new discoveries and technologies emerging regularly.
- Potential for acquisition by a larger pharmaceutical company: Given its innovative pipeline and promising clinical data, Kezar could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its portfolio of immune-mediated disease and cancer therapies. Acquisitions are common in the biotechnology industry, with larger companies often acquiring smaller firms to gain access to their technologies and product candidates. An acquisition could provide Kezar's investors with a significant return on their investment.
What Opportunities Does KZR Have?
- Expansion of KZR-616 into new indications.
- Advancement of KZR-261 into clinical development.
- Strategic partnerships and collaborations with larger companies.
What Threats Does KZR Face?
- Competition from other biotechnology and pharmaceutical companies.
- Unfavorable clinical trial results.
- Regulatory hurdles and delays.
What Are KZR's Competitive Advantages?
- Proprietary small molecule therapeutics with unique mechanisms of action.
- Patent protection for its product candidates.
- Expertise in immunoproteasome inhibition and protein secretion inhibition.
What Does KZR Do?
Kezar Life Sciences, Inc., founded in 2015 and based in South San Francisco, California, is a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics. The company targets unmet needs in immune-mediated diseases and cancer, aiming to provide innovative treatment options for patients with limited alternatives. Kezar's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-616 is in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. Beyond KZR-616, Kezar is advancing a pipeline of preclinical products, including KZR-261, a novel first-in-class protein secretion inhibitor, and KZR-TBD for oncology and immunology applications. The company's research and development efforts are focused on creating differentiated therapies that address the underlying mechanisms of disease, with the goal of improving patient outcomes and quality of life. Kezar operates primarily in the United States, conducting its clinical trials and preclinical research within the country. The company's strategy involves identifying promising drug targets, developing proprietary small molecule compounds, and advancing these compounds through preclinical and clinical development stages. Kezar's success hinges on the positive outcomes of its clinical trials and the ability to secure regulatory approvals for its product candidates.
What Products and Services Does KZR Offer?
- Develop novel small molecule therapeutics.
- Target unmet needs in immune-mediated diseases.
- Target unmet needs in cancer.
- Conduct Phase 2 clinical trials for KZR-616 in lupus nephritis, dermatomyositis, and polymyositis.
- Conduct Phase 1b clinical trials for KZR-616 in systemic lupus erythematosus and lupus nephritis.
- Advance preclinical products, including KZR-261 and KZR-TBD.
How Does KZR Make Money?
- Discovery and development of proprietary small molecule therapeutics.
- Out-licensing or partnering with larger pharmaceutical companies for commercialization.
- Generating revenue through potential future sales of approved therapies.
What Industry Does KZR Operate In?
Kezar Life Sciences operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Kezar's focus on immune-mediated diseases and cancer places it within a growing market, as these conditions affect a large and increasing patient population. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share. Kezar differentiates itself through its focus on small molecule therapeutics and its selective immunoproteasome inhibition approach.
Who Are KZR's Key Customers?
- Patients suffering from immune-mediated diseases.
- Patients suffering from cancer.
- Healthcare providers who treat these patients.
F-Score 3/9Financial Health
Kezar Life Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.05 places it in the distress zone, a signal of elevated financial risk.
ROE -58%Key Financial Metrics
Return on equity for Kezar Life Sciences, Inc. stands at -58.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -66.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -78.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 24.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -84.5%, the inverse of the P/E and a quick read on earnings relative to price.
Kezar Life Sciences, Inc. (KZR) Valuation Context
Valued at $53.86M, KZR is classified as a micro-cap stock. Relative to its peer group, KZR's quantitative score of 44/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Kezar Life Sciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-4.93.
KZR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline, indicating strong belief in upcoming clinical trial results.
- Community sentiment has turned positive as discussions around the potential of their therapies gain traction, reflecting optimism among retail investors.
- Analysts have highlighted the innovative approach of Kezar's drug candidates, which could address unmet medical needs, enhancing market perception.
- Collaborations with reputable research institutions have bolstered credibility, attracting attention from both investors and industry experts.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with many new entrants developing similar therapies, raising questions about market share.
- Recent social media sentiment has shown some skepticism, particularly regarding the timeline for FDA approvals, which could delay potential revenue.
- The volatility in biotech stocks has led to caution among investors, as past trends have shown that many companies struggle to deliver on their promises.
- Overall market conditions remain uncertain, with macroeconomic factors potentially impacting funding and investment in biotech companies like Kezar.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
KZR Latest News
-
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Yahoo! Finance: KZR News · May 19, 2026
KZR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KZR.
Price Targets
Wall Street price target analysis for KZR.
KZR MoonshotScore
What does this score mean?
The MoonshotScore rates KZR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Kezar Life Sciences, Inc. Analysis
Leadership: Christopher J. Kirk
CEO
Christopher J. Kirk serves as the Chief Executive Officer of Kezar Life Sciences, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, contributing to the advancement of novel therapies. Kirk's expertise spans across multiple therapeutic areas, including immunology and oncology. His educational background includes advanced degrees in relevant scientific disciplines, providing him with a strong foundation in the underlying science of drug discovery and development.
Track Record: Under Christopher J. Kirk's leadership, Kezar Life Sciences has advanced KZR-616 into Phase 2 clinical trials and expanded its pipeline with preclinical programs. He has overseen the company's strategic direction, focusing on the development of innovative therapies for immune-mediated diseases and cancer. Kirk has also been instrumental in securing funding and partnerships to support Kezar's research and development efforts.
What Investors Ask About Kezar Life Sciences, Inc. (KZR) — Healthcare
What does Kezar Life Sciences, Inc. do?
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer. Its lead product candidate, KZR-616, is a selective immunoproteasome inhibitor in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis. The company's pipeline also includes preclinical programs like KZR-261, a first-in-class protein secretion inhibitor, and KZR-TBD, targeting oncology and immunology. Kezar aims to create differentiated therapies that improve patient outcomes in areas with limited treatment options.
What do analysts say about KZR stock?
Analyst coverage of Kezar Life Sciences is limited, reflecting its small-cap status and early-stage development. Consensus estimates vary widely, depending on the perceived probability of success for KZR-616 and other pipeline candidates. Key valuation metrics include potential peak sales for KZR-616, discounted cash flow analysis, and comparisons to peer companies in the biotechnology sector. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization of its therapies. Investors should conduct their own due diligence and consider the inherent risks of investing in clinical-stage biotechnology companies.
What are the main risks for KZR?
Kezar Life Sciences faces several key risks inherent to its business model and the biotechnology industry. Clinical trial risk is paramount, as unfavorable results for KZR-616 or other pipeline candidates could significantly impact the company's valuation. Regulatory risk is also significant, as the FDA approval process is lengthy and uncertain. Competition from other companies developing therapies for immune-mediated diseases and cancer poses a threat to Kezar's market share. Financial risk is also a concern, as the company relies on securing additional funding to support its research and development activities. Patent expiration and intellectual property protection are also ongoing risks.
How does Kezar Life Sciences, Inc. manage patent expiration risks?
Kezar Life Sciences actively manages patent expiration risks through a multi-faceted approach. The company seeks patent protection for its novel small molecule therapeutics, including KZR-616 and KZR-261, covering composition of matter, methods of use, and manufacturing processes. Kezar also pursues patent term extensions where available to maximize the exclusivity period for its products. Furthermore, the company continuously monitors the competitive landscape and actively defends its intellectual property rights against infringement. Kezar's lifecycle management strategies include developing new formulations and indications for its existing products to extend their market exclusivity beyond the initial patent term. The company also explores opportunities to acquire or license new intellectual property to strengthen its pipeline and mitigate the impact of patent expirations.
What revenue streams does Kezar Life Sciences, Inc. have in healthcare?
As a clinical-stage biotechnology company, Kezar Life Sciences currently does not have any commercial revenue streams. The company's primary focus is on research and development, with the goal of developing and commercializing novel small molecule therapeutics for immune-mediated diseases and cancer. Potential future revenue streams for Kezar include product sales following regulatory approval of KZR-616 or other pipeline candidates, licensing agreements with larger pharmaceutical companies, and milestone payments related to the achievement of clinical and regulatory milestones. The timing and magnitude of these potential revenue streams are highly uncertain and dependent on the successful completion of clinical trials and regulatory approvals.
What are the key factors to evaluate for KZR?
Kezar Life Sciences, Inc. (KZR) holds an AI score of 44/100 (low). Not financial advice.
How frequently does KZR data refresh on this page?
KZR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KZR's recent stock price performance?
Kezar Life Sciences, Inc. (KZR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product candidate (KZR-616) in Phase 2 clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.